Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

BIOGEN's SECOND VACCINE PROJECT FOCUSES ON MALARIA in a joint venture with Behringwerke, the biotech firm announced in a Feb. 11 press release. Under the agreement, Hoechst subsidiary Behringwerke will develop and market the vaccine using genetic engineering technology supplied by Biogen. "This agreement, which brings together Biogen's technology and Behringwerke's expertise in the manufacturing and marketing of biologicals, will speed the development of this much-needed vaccine," Biogen Chairman and CEO James Vincent stated. "Using the genetically-engineered antigens developed by Biogen, Behringwerke can apply its extensive scientific and manufacturing resources to bring this important product rapidly to market." Unlike recombinant vaccines under development by Roche and Smith-Kline, the Biogen/Behringwerke vaccine targets the merozoite or "blood" phase of malaria rather than the initial sporozoite phase. Biogen explained that it has cloned and expressed a number of surface proteins of the malaria parasite's merozoite form, which occurs after the original mosquitotransmitted sporozoite has matured in the liver. The release noted that Behringwerke "will use the merozoite antigens in a vaccine intended to interrupt the disease cycle by preventing the malaria merozoites from infecting red blood cells." Biogen's first effort in the vaccine area centered around hepatitis B. Currently, the Wellcome Foundation and Green Cross are developing a hepatitis B vaccine under license from the biotech firm. Biogen noted that the vaccine is currently in Phase II clinicals in Japan.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts